Sorted By Test Name - Mayo Medical Laboratories

FGLIP
91097
GBM
8106
Disease Diagnostic Testing Algorithm in Special Instructions.
Useful For: Evaluating patients suspected of having celiac disease; this includes patients with
symptoms compatible with celiac disease, patients with atypical symptoms, and individuals at increased
risk of celiac disease Evaluating the response to treatment with a gluten-free diet
Interpretation: Positive test results for deamidated gliadin antibodies, IgA or IgG, are consistent with
the diagnosis of celiac disease. Negative results indicate a decreased likelihood of celiac disease.
Decreased levels of deamidated gliadin antibodies, IgA or IgG, following treatment with a gluten-free diet
are consistent with adherence to the diet. Persistence of high levels of antibodies following dietary
treatment suggest poor adherence to the diet or the presence of refractory disease.
Reference Values:
Negative: 30.0 U
Clinical References: 1. Green PH, Cellier C: Celiac disease. New Eng J Med 2007;357:1731-1743
2. Green PH, Jabri B: Celiac disease. Annu Rev Med 2006;57:207-221 3. Harrison MS, Wehbi M,
Obideen K: Celiac disease: More common than you think. Cleve Clinic J Med 2007;74:209-215 4. Dale
JC, Homburger HA, Masoner DE, Murray JA: Update on celiac disease: New standards and new tests.
Mayo Communique 2008;33(6):1-9 5. Rashtak S, Ettore MW, Homburger HA, Murray JA: Comparative
usefulness of deamidated gliadin antibodies in the diagnosis of celiac disease. Clin Gastroenterol Hepatol
2008 Apr;6(4):426-432 6. Sugai E, Vazquez H, Nachman F, et al: Accuracy of testing for antibodies to
synthetic gliadin-related peptides in celiac disease. Clin Gastroenterol Hepatol 2006;4:1112-1117
Glipizide (Glucotrol)
Reference Values:
Reporting Limit: 80 ng/mL
Plasma insulin concentrations have been shown to increase only
when plasma glipizide concentrations exceeded 200 ng/mL.
Toxic range has not been established.
Test Performed by: Medtox Laboratories, Inc.
402 W. County Road D
St. Paul, MN 55112
Glomerular Basement Membrane Antibodies, IgG, Serum
Clinical Information: Antibodies to glomerular basement membrane antigens (GBM antibodies)
cause glomerulonephritis, Goodpasture syndrome (glomerulonephritis, often with rapid onset renal
failure, and pulmonary hemorrhage), and, less commonly, pulmonary hemosiderosis.(1) Nephrogenic
GBM antigens are associated with the noncollagenous carboxyl extension of type IV procollagen. The
immunologic stimuli that elicit production of GBM antibodies are not known. There is some evidence of a
genetic association with HLA-DR2. GBM antibody-mediated glomerulonephritis and Goodpasture
syndrome occur with a bimodal age distribution primarily in males ages 20 to 40 and in patients older
than age 50. Glomerulonephritis without pulmonary involvement is more common in the older age group,
and shows a female predominance.
Useful For: Evaluating patients with rapid onset renal failure or pulmonary hemorrhage, as an aid in
the diagnosis of Goodpasture syndrome
Interpretation: Positive results are consistent with Goodpasture syndrome. Glomerular basement
membrane antibodies detected by immunoassay have been reported to be highly specific for Goodpasture
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 818